IP Library Granted Patent US 7,705,026
Granted Patent B2
US 7,705,026 · App. 12/275,941 · Granted Apr 27, 2010

Biaryl heterocyclic compounds and methods of making and using the same

Assignee: Rib-X Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,705,026
App. No.
12/275,941
Granted
Apr 27, 2010
Kind
B2
Abstract

The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.

Claims (14)

1. A pharmaceutically acceptable salt of a tautomer of a compound having the structure

2. The salt of claim 1 , wherein the salt is a non-toxic inorganic or organic acid salt.

3. The salt of claim 2 , wherein the nontoxic inorganic or organic acid is selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicyclic, stearic, subacetic, succinic, sulfamic, sutfanilic, sulfuric, tannic, tartaric, and toluene sulfonic.

4. The salt of claim 2 , wherein the acid is hydrochloric.

5. A pharmaceutical composition comprising the salt of claim 1 and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising the salt of claim 2 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising the salt of claim 3 and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising the salt of claim 4 and a pharmaceutically acceptable carrier.

9. A method of ameliorating a symptom of a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of a salt or composition according to any one of claims 1 - 8 .

10. The method according to claim 9 , wherein the salt or composition is administered orally, parentally, or topically.

11. A method of ameliorating a symptom of a disorder in a mammal comprising the step of administering to the mammal an effective amount of a salt or composition according to any one of claims 1 - 8 wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.

12. The method according to claim 1 , wherein the salt or composition is administered orally, parentally, or topically.

13. A method of ameliorating a symptom of microbial infection in a mammal by administering to the mammal prior to undergoing a surgical procedure an effective amount of a salt or composition according to any one of claims 1 - 8 .

14. The method according to claim 13 , wherein the salt or composition is administered orally, parentally, or topically.

Assignments (8)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0824, REEL 061314 AND FRAME 0572 AND REEL 068260 AND FRAME 0283 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 074576/0471 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 061314/0572 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA SUBSIDIARY CORP.
To: SILICON VALLEY BANK
Reel/Frame 054836/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2019
From: MELINTA THERAPEUTICS, INC.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 048030/0489 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: SPRINGER, DANE M.
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 033811/0144 →
CHANGE OF NAME Recorded Sep 24, 2014
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 033813/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2014
From: ZHOU, JIACHENG; BHATTACHARJEE, ASHOKE; CHEN, SHILI; CHEN, YI; FARMER, JAY J.; GOLDBERG, JOEL A.; HANSELMANN, ROGER; LOU, RONGLIANG; ORBIN, ALIA; OYELERE, ADEGBOYEGA K.; SALVINO, JOSEPH M.; TRAN, JENNIFER; WANG, DEPING; WU, YUSHENG
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 033811/0114 →
Continuity (9)
Continuation 1148676900 · Jul 14, 2006
Continuation 1111880800 · Apr 29, 2005
Continuation 1085947600 · Jun 2, 2004
Provisional Application 6047543000 · Jun 3, 2003
Provisional Application 6047545300 · Jun 3, 2003
Provisional Application 6049085500 · Jul 29, 2003
Provisional Application 6052973100 · Dec 15, 2003
Provisional Application 6053158400 · Dec 19, 2003
Related Publication 20090118502A1 · May 7, 2009